These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 12716442)

  • 21. Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors.
    Komers R; Anderson S; Epstein M
    Am J Kidney Dis; 2001 Dec; 38(6):1145-57. PubMed ID: 11728945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The "aspirin" of the new millennium: cyclooxygenase-2 inhibitors.
    Buttar NS; Wang KK
    Mayo Clin Proc; 2000 Oct; 75(10):1027-38. PubMed ID: 11040851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cox-2: Where are we in 2003? - The role of cyclooxygenase-2 in bone repair.
    Einhorn TA
    Arthritis Res Ther; 2003; 5(1):5-7. PubMed ID: 12716441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclo-oxygenase isoenzymes: physiological and pharmacological role.
    Kam PC; See AU
    Anaesthesia; 2000 May; 55(5):442-9. PubMed ID: 10792135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal effects of COX-2-selective inhibitors.
    Brater DC; Harris C; Redfern JS; Gertz BJ
    Am J Nephrol; 2001; 21(1):1-15. PubMed ID: 11275626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COX-2 inhibitors: a review.
    Houston AM; Teach SJ
    Pediatr Emerg Care; 2004 Jun; 20(6):396-9; quiz 400-2. PubMed ID: 15179150
    [No Abstract]   [Full Text] [Related]  

  • 27. Introduction. The role of COX-2-specific inhibitors in clinical practice.
    Lipsky PE
    Am J Med; 2001 Feb; 110 Suppl 3A():1S-2S. PubMed ID: 11173042
    [No Abstract]   [Full Text] [Related]  

  • 28. Cardiovascular events and COX-2 inhibitors.
    Konstam MA; Demopoulos LA
    JAMA; 2001 Dec; 286(22):2809; author reply 2811-2. PubMed ID: 11735743
    [No Abstract]   [Full Text] [Related]  

  • 29. Cardiovascular events and COX-2 inhibitors.
    White WB; Whelton A
    JAMA; 2001 Dec; 286(22):2811-2. PubMed ID: 11735749
    [No Abstract]   [Full Text] [Related]  

  • 30. The second generation of COX-2 inhibitors: clinical pharmacological point of view.
    Stichtenoth DO
    Mini Rev Med Chem; 2004 Aug; 4(6):617-24. PubMed ID: 15279595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The coxibs, selective inhibitors of cyclooxygenase-2.
    Rich SA
    N Engl J Med; 2001 Dec; 345(23):1709. PubMed ID: 11759657
    [No Abstract]   [Full Text] [Related]  

  • 32. Cyclooxygenase-2: a therapeutic target.
    Turini ME; DuBois RN
    Annu Rev Med; 2002; 53():35-57. PubMed ID: 11818462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular events and COX-2 inhibitors.
    Grant KD
    JAMA; 2001 Dec; 286(22):2809; author reply 2811-2. PubMed ID: 11735744
    [No Abstract]   [Full Text] [Related]  

  • 34. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors.
    de Gaetano G; Donati MB; Cerletti C
    Trends Pharmacol Sci; 2003 May; 24(5):245-52. PubMed ID: 12767724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Specific cyclo-oxygenase-2 inhibitors in cardiovascular pathology].
    Monsuez JJ
    Arch Mal Coeur Vaiss; 2004 Jun; 97(6):632-40. PubMed ID: 15283037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: clinical implications.
    Meagher EA
    Drug Saf; 2003; 26(13):913-24. PubMed ID: 14583067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular events and COX-2 inhibitors.
    McGeer PL; McGeer EG; Yasojima K
    JAMA; 2001 Dec; 286(22):2810; author reply 2811-2. PubMed ID: 11735747
    [No Abstract]   [Full Text] [Related]  

  • 38. The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition.
    Singh-Ranger G; Mokbel K
    Eur J Surg Oncol; 2002 Nov; 28(7):729-37. PubMed ID: 12431470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective cyclooxygenase-2 inhibitors as potential therapeutic agents for inflammatory diseases.
    Chan CC; Rodger IW
    Adv Exp Med Biol; 1997; 407():157-61. PubMed ID: 9321947
    [No Abstract]   [Full Text] [Related]  

  • 40. Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors.
    Schnitzer TJ
    Clin Ther; 2001 Mar; 23(3):313-326; discussion 311-2. PubMed ID: 11318071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.